Ledgy AG is a technology company based in Zurich, Switzerland, founded in 2017. It operates a Software-as-a-Service platform designed to facilitate the management and exchange of securities in private companies. The platform serves as an online share register, enabling founders, employees, and investors to manage equity effectively. Ledgy's tools allow companies to oversee employee incentive plans, model financing rounds, and generate reports for investors, thereby fostering trust in capital tables. The platform features personalized dashboards for employees to track their vested shares and for investors to monitor portfolio performance. By digitizing the equity management process and ensuring error-free capital tables, Ledgy provides clarity and insights for all stakeholders involved, ultimately supporting companies in attracting and retaining talent while enhancing investor relations.
Morgen is a time management platform that simplifies the scheduling process by integrating multiple calendars and task management tools into a single application. As the complexity of time management increases, Morgen addresses this challenge by offering a holistic solution that allows users to plan, organize, and optimize their schedules effectively. The platform combines various calendar systems and communication channels, enabling users to manage all events, tasks, lists, and reminders in one place. With its native scheduling tool, Morgen helps individuals and teams reduce meeting chaos and streamline their daily activities, making time management more efficient and less fragmented.
turicode Inc. develops software as a service (SaaS) platform for document processing. Its software reads and understands documents such as PDFs, scans, and emails. The company’s MINT.extract platform helps companies and their employees to digitize document. It serves legal and tax, financial industry, healthcare, logistics, insurance, and archives industries. turicode Inc. was founded in 2016 and is based in Winterthur, Switzerland.
Ledgy AG is a technology company based in Zurich, Switzerland, founded in 2017. It operates a Software-as-a-Service platform designed to facilitate the management and exchange of securities in private companies. The platform serves as an online share register, enabling founders, employees, and investors to manage equity effectively. Ledgy's tools allow companies to oversee employee incentive plans, model financing rounds, and generate reports for investors, thereby fostering trust in capital tables. The platform features personalized dashboards for employees to track their vested shares and for investors to monitor portfolio performance. By digitizing the equity management process and ensuring error-free capital tables, Ledgy provides clarity and insights for all stakeholders involved, ultimately supporting companies in attracting and retaining talent while enhancing investor relations.
Araris Biotech AG is a biotechnology start-up based in Zurich, Switzerland, that specializes in developing antibody-drug conjugate (ADC) linker technology for targeted chemotherapy. Founded in 2019, the company focuses on creating a platform that facilitates the rapid production of high-quality ADCs without the need for extensive engineering of antibodies or cell lines. This approach allows for the direct use of "off-the-shelf" antibodies, enabling the site-specific modification of ADCs within days, while ensuring robust quality control and analysis. Araris' technology is designed to deliver potent drugs directly to cancer cells, minimizing exposure to healthy tissues and thereby improving safety and tolerability for patients. The company's innovative ADC technology is supported by two patents, underscoring its commitment to advancing anti-cancer treatment options.
Araris Biotech AG is a biotechnology start-up based in Zurich, Switzerland, that specializes in developing antibody-drug conjugate (ADC) linker technology for targeted chemotherapy. Founded in 2019, the company focuses on creating a platform that facilitates the rapid production of high-quality ADCs without the need for extensive engineering of antibodies or cell lines. This approach allows for the direct use of "off-the-shelf" antibodies, enabling the site-specific modification of ADCs within days, while ensuring robust quality control and analysis. Araris' technology is designed to deliver potent drugs directly to cancer cells, minimizing exposure to healthy tissues and thereby improving safety and tolerability for patients. The company's innovative ADC technology is supported by two patents, underscoring its commitment to advancing anti-cancer treatment options.
MESA Imaging specializes in the development and production of 3D time-of-flight cameras designed to capture full 3D images at video frame rates. The company utilizes the Time-of-Flight (TOF) principle and incorporates advanced technologies, such as the silo pixel architecture and the SR4000 sensor chip, to enhance distance measurement capabilities. MESA Imaging supplies its innovative camera systems to various sectors, including video gaming, machine vision, automotive, and robotics, thereby contributing to advancements in image-related industries.
Ledgy AG is a technology company based in Zurich, Switzerland, founded in 2017. It operates a Software-as-a-Service platform designed to facilitate the management and exchange of securities in private companies. The platform serves as an online share register, enabling founders, employees, and investors to manage equity effectively. Ledgy's tools allow companies to oversee employee incentive plans, model financing rounds, and generate reports for investors, thereby fostering trust in capital tables. The platform features personalized dashboards for employees to track their vested shares and for investors to monitor portfolio performance. By digitizing the equity management process and ensuring error-free capital tables, Ledgy provides clarity and insights for all stakeholders involved, ultimately supporting companies in attracting and retaining talent while enhancing investor relations.
Xeltis AG is a clinical-stage medical device company based in Zurich, Switzerland, with additional research and development facilities in Eindhoven, the Netherlands. Founded in 2006, Xeltis focuses on developing bio-absorbable heart valves and blood vessels that facilitate the body's natural healing processes. Its innovative technology, known as RestoreX, employs a therapeutic approach called Endogenous Tissue Restoration (ETR), which allows patients' own bodies to generate new heart valves. Through ETR, the porous structure of Xeltis' heart valves, made from bioabsorbable polymers, enables tissue to integrate with the implant, gradually forming a fully functional valve while the device itself is absorbed by the body. This groundbreaking approach aims to transform the treatment of heart valve disease by restoring natural heart valve function.
Advanon AG, based in Zurich, Switzerland, operates an online financial services platform that specializes in invoice financing for small and medium-sized enterprises (SMEs). Founded in 2015, the platform allows businesses to pre-finance their invoices, enabling them to access liquidity without the long wait times typically associated with customer payments, which can range from 30 to 120 days. This service provides SMEs with flexible financing options that help strengthen their cash flow and support growth. Advanon is recognized as a financial intermediary and complies with regulatory standards set by the Swiss Financial Market Supervisory Authority (FINMA) under the Anti Money Laundering Act.
Inositec AG is a biotechnology company based in Zurich, Switzerland, established in 2015 as a spin-off from ETH Zurich. The company specializes in the development of drug therapies derived from its proprietary Inositune platform, which utilizes inositol phosphate analogs with adjustable properties. Inositec's lead product, INS-5010, is a non-antibiotic therapy designed to target colon infections caused by Clostridium difficile. Additionally, the company addresses soft tissue calcification disorders, focusing on vascular and renal calcification, including orphan indications. By selectively modifying the phosphate groups in inositol phosphate compounds, Inositec aims to create molecules with improved drug-like properties tailored for specific therapeutic applications.
Xeltis AG is a clinical-stage medical device company based in Zurich, Switzerland, with additional research and development facilities in Eindhoven, the Netherlands. Founded in 2006, Xeltis focuses on developing bio-absorbable heart valves and blood vessels that facilitate the body's natural healing processes. Its innovative technology, known as RestoreX, employs a therapeutic approach called Endogenous Tissue Restoration (ETR), which allows patients' own bodies to generate new heart valves. Through ETR, the porous structure of Xeltis' heart valves, made from bioabsorbable polymers, enables tissue to integrate with the implant, gradually forming a fully functional valve while the device itself is absorbed by the body. This groundbreaking approach aims to transform the treatment of heart valve disease by restoring natural heart valve function.
Xeltis AG is a clinical-stage medical device company based in Zurich, Switzerland, with additional research and development facilities in Eindhoven, the Netherlands. Founded in 2006, Xeltis focuses on developing bio-absorbable heart valves and blood vessels that facilitate the body's natural healing processes. Its innovative technology, known as RestoreX, employs a therapeutic approach called Endogenous Tissue Restoration (ETR), which allows patients' own bodies to generate new heart valves. Through ETR, the porous structure of Xeltis' heart valves, made from bioabsorbable polymers, enables tissue to integrate with the implant, gradually forming a fully functional valve while the device itself is absorbed by the body. This groundbreaking approach aims to transform the treatment of heart valve disease by restoring natural heart valve function.
Delenex Therapeutics AG is a Swiss biotechnology company focused on developing therapeutic antibody fragments to address serious medical conditions with significant unmet needs. The company specializes in creating antibody fragments intended for local or topical application, leveraging the advantages of antibody therapy while minimizing systemic exposure. Delenex's technology has been clinically validated, enabling the production of antibodies that demonstrate high affinity, solubility, and stability, coupled with a low risk of immunogenicity. This approach aims to enhance therapeutic efficacy while reducing potential side effects associated with traditional systemic antibody treatments.
Sonic Emotion AG, founded in 2002 and headquartered in Zurich, Switzerland, specializes in advanced audio solutions that create immersive sound experiences. The company's flagship technology, Sonic Emotion Absolute 3D, enables natural 3D sound reproduction using sound field control from as few as two channels, allowing for compact audio setups suitable for a variety of environments. Sonic Emotion AG caters to diverse markets, providing audio solutions for 3D cinemas, events, trade fairs, museums, theme parks, and dance shows. Additionally, the company offers audio simulation services, OEM licensing solutions, and a sound enhancement application named Headquake for Apple i-device products. With research facilities in France and sales offices across Asia, including China, Hong Kong, Taiwan, and Japan, Sonic Emotion AG is positioned to deliver cutting-edge audio technology globally.
Spinelab, based in Winterthur, Switzerland, is a privately held company dedicated entirely to the development of a new generation of spinal motion preservation devices. Spinelab Ltd. is the manufacturer and distributor of the CE-marked implant and instrument system Elaspine™ for the treatment of degenerative lumbar spine disease.
Delenex Therapeutics AG is a Swiss biotechnology company focused on developing therapeutic antibody fragments to address serious medical conditions with significant unmet needs. The company specializes in creating antibody fragments intended for local or topical application, leveraging the advantages of antibody therapy while minimizing systemic exposure. Delenex's technology has been clinically validated, enabling the production of antibodies that demonstrate high affinity, solubility, and stability, coupled with a low risk of immunogenicity. This approach aims to enhance therapeutic efficacy while reducing potential side effects associated with traditional systemic antibody treatments.
Delenex Therapeutics AG is a Swiss biotechnology company focused on developing therapeutic antibody fragments to address serious medical conditions with significant unmet needs. The company specializes in creating antibody fragments intended for local or topical application, leveraging the advantages of antibody therapy while minimizing systemic exposure. Delenex's technology has been clinically validated, enabling the production of antibodies that demonstrate high affinity, solubility, and stability, coupled with a low risk of immunogenicity. This approach aims to enhance therapeutic efficacy while reducing potential side effects associated with traditional systemic antibody treatments.
Spinelab, based in Winterthur, Switzerland, is a privately held company dedicated entirely to the development of a new generation of spinal motion preservation devices. Spinelab Ltd. is the manufacturer and distributor of the CE-marked implant and instrument system Elaspine™ for the treatment of degenerative lumbar spine disease.
ESBATech, founded in 1998 as a spin-off from the University of Zurich, specializes in the development of fully human antibody fragments for therapeutic purposes. The company utilizes its proprietary single-chain antibody frameworks to create product candidates targeting clinically relevant diseases. ESBATech aims to deliver high concentrations of these therapeutic antibody fragments to specific sites while minimizing systemic exposure, thereby reducing the risk of adverse drug reactions. In addition to its innovative antibody development, the company offers drug development services and manages various development programs, positioning itself as a leader in the field of targeted therapies.
Spinelab, based in Winterthur, Switzerland, is a privately held company dedicated entirely to the development of a new generation of spinal motion preservation devices. Spinelab Ltd. is the manufacturer and distributor of the CE-marked implant and instrument system Elaspine™ for the treatment of degenerative lumbar spine disease.
ESBATech, founded in 1998 as a spin-off from the University of Zurich, specializes in the development of fully human antibody fragments for therapeutic purposes. The company utilizes its proprietary single-chain antibody frameworks to create product candidates targeting clinically relevant diseases. ESBATech aims to deliver high concentrations of these therapeutic antibody fragments to specific sites while minimizing systemic exposure, thereby reducing the risk of adverse drug reactions. In addition to its innovative antibody development, the company offers drug development services and manages various development programs, positioning itself as a leader in the field of targeted therapies.
Visonys
Venture Round in 2006
Visonys develops information security software for financial institutions, e-commerce, industrial companies, and authorities. It offers visonysAirlock, which provides differing authorization to clients, partners, and employees for relevant applications. The company's products are used in Web applications that process confidential information or manage business transactions and processes. The company was founded in 2002 as Seclutions AG and changed its name to Visonys AG in February, 2006. The company is based in Zurich, Switzerland.
Avalon Photonics
Venture Round in 2003
Avalon Photonics produces world-class VCSELs (vertical cavity surface emitting lasers) for datacom, sensing, and measurement markets. These devices are enabling volume applications due to their exceptional performance, lower power consumption, and volume cost reduction.Avalon also produces unique, patent-protected, single-spatial-mode VCSELs with unsurpassed specifications required for many sensing and measurement applications. Avalon’s ISO 9001 production line achieves high quality, exceptional uniformity, and telecom-grade reliability devices. VCSELs can be provided from bare die up to fully packaged units with temperature control and fiber pigtailing.